Shares in Swiss biotech AC Immune have risen sharply after it said a vaccine in development for Alzheimer’s disease (AD) hit the mark in a phase 1/2 trial. ACI-35.030, partnered with Johnson & Johnson ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results